Epstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt's Lymphoma Cells

ABSTRACT It has been suggested that Epstein-Barr virus (EBV) might suppress antibody maturation either by facilitating bypass of the germinal center reaction or by inhibiting hypermutation directly. However, by infecting the Burkitt's lymphoma (BL) cell line Ramos, which hypermutates constitutively and can be considered a transformed analogue of a germinal center B cell, with EBV as well as by transfecting it with selected EBV latency genes, we demonstrate that expression of EBV gene products does not lead to an inhibition of hypermutation. Moreover, we have identified two natural EBV-positive BL cell lines (ELI-BL and BL16) that hypermutate constitutively. Thus, contrary to expectations, EBV gene products do not appear to affect somatic hypermutation.

[1]  D. Thorley-Lawson,et al.  Cells Expressing the Epstein-Barr Virus Growth Program Are Present in and Restricted to the Naive B-Cell Subset of Healthy Tonsils , 2000, Journal of Virology.

[2]  D. Thorley-Lawson,et al.  Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Rajewsky,et al.  EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. , 2000, Immunity.

[4]  D. Thorley-Lawson,et al.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. , 2000, Immunity.

[5]  J. Banchereau,et al.  T Cells Can Induce Somatic Mutation in B Cell Receptor-Engaged BL2 Burkitt’s Lymphoma Cells Independently of CD40-CD40 Ligand Interactions1 , 2000, The Journal of Immunology.

[6]  N. Raab-Traub,et al.  Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. , 1999, Science.

[7]  M. Neuberger,et al.  TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. , 1998, Immunity.

[8]  V. Godfrey,et al.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. O’Donnell,et al.  Human RPA (hSSB) interacts with EBNA1, the latent origin binding protein of Epstein-Barr virus. , 1998, Nucleic acids research.

[10]  A. Rickinson,et al.  Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain , 1997, Journal of virology.

[11]  H. Yoshiyama,et al.  Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells , 1996, Journal of virology.

[12]  Karin Klein,et al.  Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. , 1994, Blood.

[13]  G. Peters,et al.  EBNA‐2 and EBNA‐LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein‐Barr virus. , 1994, The EMBO journal.

[14]  E. Kieff,et al.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells , 1992, Journal of virology.

[15]  H. Stein,et al.  Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. , 1992, Blood.

[16]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[17]  E. Kieff,et al.  Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells. , 1991, Journal of virology.

[18]  M. Rowe,et al.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein , 1990, Journal of virology.

[19]  E. Kieff,et al.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.

[20]  E. Kieff,et al.  Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins , 1989, Journal of virology.

[21]  I. Ernberg,et al.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines , 1987, Journal of virology.

[22]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[23]  E. Kieff,et al.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. , 1987, The Journal of general virology.

[24]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.

[25]  M. Epstein,et al.  Paired epstein‐barr virus‐carrying lymphoma and lymphoblastoid cell lines Burkitt's lymphoma patients: Comparative sensitivity to non‐specific and to allo‐specific cytotoxic responses in vitro , 1984, International journal of cancer.

[26]  G. Miller,et al.  Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. , 1979, Virology.

[27]  B. Giovanella,et al.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. , 1975, Intervirology.